title: Follow-up protected specimen brushes to assess treatment in nosocomial pneumonia.
abstract: To prospectively determine the bacteriologic and clinical efficacy of antimicrobial therapy for nosocomial bacterial pneumonia selected based upon information provided by cultures of protected specimen brush (PSB) samples obtained during bronchoscopy, 76 consecutive patients with ventilator-associated pneumonia were studied using follow-up quantitative PSB cultures obtained after 3 days of treatment. Of the 173 microorganisms initially present in the PSB samples, only 11 (6%) were not eradicated by antimicrobial therapy, including three recovered at high (> or = 10(3) cfu/ml) concentrations. Thirty-two emerging pathogens, including nine at high concentrations, were also detected; 26 of them (81%) were resistant to the initial antibiotics administered. Of the 76 patients included in the study, cultures of follow-up PSB samples identified 51 in whom the infection site in the lung was completely sterilized, 16 with low-grade infection, and only nine with persistent high-grade infection. Analysis of clinical outcome within the 15 days after the initiation of antimicrobial therapy demonstrated clinical improvement in 62 of 67 (93%) patients in whom the site of infection was contained by treatment as compared with four of 9 (44%) patients with persistent high-grade infection (p < 0.01). These data suggest that appropriate antimicrobial therapy for ventilator-associated pneumonia results in the control of the initial infection in 88% of the patients. However, an early superinfection caused by multiresistant pathogens can occur in a small subset of these patients. When follow-up PSB cultures were negative, an improved outcome was noted.
authors.affiliation: Service de Réanimation Médicale, Hôpital Bichat, Paris, France.
authors.forename: P
authors.initials: P
authors.lastname: Montravers
authors.forename: J Y
authors.initials: JY
authors.lastname: Fagon
authors.forename: J
authors.initials: J
authors.lastname: Chastre
authors.forename: M
authors.initials: M
authors.lastname: Lecso
authors.forename: M C
authors.initials: MC
authors.lastname: Dombret
authors.forename: J L
authors.initials: JL
authors.lastname: Trouillet
authors.forename: C
authors.initials: C
authors.lastname: Gibert
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001419:Bacteria / Q000302:isolation & purification*; D001424:Bacterial Infections / Q000188:drug therapy / Q000382:microbiology; D001999:Bronchoscopy; D003428:Cross Infection / Q000188:drug therapy* / Q000382:microbiology*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011014:Pneumonia / Q000188:drug therapy* / Q000382:microbiology*; D011446:Prospective Studies; D012121:Respiration, Artificial / Q000009:adverse effects; D013048:Specimen Handling
chemical_list: D000900:Anti-Bacterial Agents